Betrixaban study free download

Download full-text PDF Read full Join for free. Public Full-text 1. Available via based on data from the phase III Acute Medically Ill VTE Prevention with Extended Duration Betrixaban study. Of these patients, were found to be eligible to participate in the study and underwent randomization ( in the betrixaban group and in the enoxaparin group). Download Free PDF Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients: An APEX Trial Substudy (Acute Medically Ill Venous Thromboembolism Prevention With Extended Duration Betrixaban).

In this study, betrixaban was selected due to its recent approval by the U.S. FDA and because of its molecular structure, which contains an aryl amidinyl moiety with dimethylamine group. Download: Download high-res image (77KB) Download: Download full-size image; Fig. 1. Chemical structure of betrixaban. Betrixaban is not an inducer of CYP1A2, 2C9, or 3A4 activity. 17 Betrixaban is not an inducer or inhibitor of CYP enzymes. 3. Betrixaban is a substrate of P-gp, and concomitant use of P-gp inhibitors (eg, amiodarone, azithromycin, verapamil, ketoconazole, clarithromycin) results in increased exposure to betrixaban. The rate of elevated alanine aminotransferase (3 times upper limit of normal) was not worse than control in EXPLORE-Xa (betrixaban vs warfarin: % vs %) and EXPERT study (betrixaban vs enoxaparin: % vs %, at discharge). 12,13 The elevation in alanine aminotransferase was transient and did not show evidence of a dose-dependent.

Betrixaban is a non-vitamin K oral anticoagulant whose action is driven by the competitive and reversible inhibition of the factor Xa 1. It was selected among all lead compounds due to its low hERG channel affinity while sustaining its factor Xa inhibition capacity 3. Betrixaban is an oral anticoagulant and direct inhibitor of factor Xa which is used to decrease the risk of deep vein thrombosis and pulmonary embolus in hospitalized patients at high risk for venous thromboses. Betrixaban has been linked to a low rate of serum aminotransferase elevations during therapy, but has not been linked to. The mean age of study participants was 76 years; 45% were male; 13% had had a stroke; and 45% had congestive heart failure. 10 The patient characteristics of the 2 groups were quite similar with the only difference between the 2 groups being a mild imbalance in the incidence of a history of stroke (% [ of ] for betrixaban versus